Related Experiment Video

Updated: Apr 25, 2026

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging
08:30

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging

Published on: September 11, 2011

18.9K

Dramatic decrease in fluoroquinolones in the pediatric population in Korea

Ju-Young Shin1, Mi Hee Kim, Sun Mi Shin

  • 1Korea Institute of Drug Safety and Risk Management (KIDS), Seoul, Korea.

Pharmacoepidemiology and Drug Safety
|August 16, 2014
PubMed

Insights

Korean regulatory actions significantly reduced fluoroquinolone prescribing in pediatric patients. This study highlights the impact of regulatory measures on antibiotic use in children, decreasing fluoroquinolone prescriptions by over 94%.

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Pediatric Pharmacology
  • Public Health Policy

Background:

  • Fluoroquinolones are potent antibiotics with potential risks, particularly in pediatric populations.
  • Regulatory actions are often implemented to mitigate adverse drug events and optimize antibiotic stewardship.
  • Understanding prescribing pattern shifts is crucial for evaluating the effectiveness of regulatory interventions.

Purpose of the Study:

  • To evaluate the impact of regulatory actions on fluoroquinolone prescribing patterns in pediatric patients.
  • To quantify the change in fluoroquinolone use before and after the implementation of regulatory measures.

Main Methods:

  • A time series analysis was conducted using the Korea Health Insurance Review and Assessment Service National Patients Sample database.
  • Pediatric patients (under 18 years) prescribed antibiotics between January 2009-December 2011 were included.
  • Fluoroquinolone use was defined by the prescription of specific fluoroquinolone agents; monthly user numbers and proportions were calculated pre- and post-regulation.

Main Results:

  • A total of 4,945,169 antibiotic prescriptions in 484,914 pediatric patients were analyzed.
  • Fluoroquinolone use decreased from 4.81% pre-regulation to 0.26% in the year following regulatory action.
  • This represents a significant 94.55% relative reduction in pediatric fluoroquinolone prescribing.

Conclusions:

  • Korean regulatory actions effectively reduced the use of fluoroquinolones in the pediatric population.
  • The findings demonstrate the successful implementation of policy to improve antibiotic stewardship in children.
  • This study underscores the importance of regulatory oversight in managing the use of potentially high-risk medications.
Abstract

Keywords:
drug utilization reviewfluoroquinolonepediatricspharmacoepidemiologyregulatory action

More Related Videos

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

20.3K
Optimization of a Quantitative Micro-neutralization Assay10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

24.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
399
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
125
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
544
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K